Genentech Completes Enrollment in Phase 3 Trial of Actemra as Scleroderma Treatment
Genentech has completed patient enrollment in a Phase 3 clinical trial evaluating Actemra (tocilizumab) as a treatment for scleroderma patients. It has now enrolled 211 patients worldwide for a trial that will be conducted at 106 sites. The focuSSced study (NCT02453256) will be assessing the effectiveness and…